@article{0cc48961d9b248d79fbc21e554380ee1,
title = "Cardiovascular events and intensity of treatment in polycythemia vera",
abstract = "Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial.",
keywords = "Aged, Antineoplastic Agents, Cardiovascular Diseases, Combined Modality Therapy, Female, Follow-Up Studies, Hematocrit, Humans, Hydroxyurea, Janus Kinase 2, Male, Middle Aged, Phlebotomy, Polycythemia Vera, Thrombosis, Aged, Antineoplastic Agents, Cardiovascular Diseases, Combined Modality Therapy, Female, Follow-Up Studies, Hematocrit, Humans, Hydroxyurea, Janus Kinase 2, Male, Middle Aged, Phlebotomy, Polycythemia Vera, Thrombosis",
author = "Roberto Marchioli and Guido Finazzi and Giorgina Specchia and Rossella Cacciola and Riccardo Cavazzina and Daniela Cilloni and {De Stefano}, Valerio and Elena Elli and Alessandra Iurlo and Roberto Latagliata and Francesca Lunghi and Monia Lunghi and Marfisi, {Rosa Maria} and Pellegrino Musto and Arianna Masciulli and Caterina Musolino and Nicola Cascavilla and Giovanni Quarta and Randi, {Maria Luigia} and Davide Rapezzi and Marco Ruggeri and Elisa Rumi and Scortechini, {Anna Rita} and Simone Santini and Marco Scarano and Sergio Siragusa and Antonio Spadea and Alessia Tieghi and Emanuele Angelucci and Giuseppe Visani and Vannucchi, {Alessandro Maria} and Tiziano Barbui",
year = "2013",
doi = "10.1056/NEJMoa1208500",
language = "English",
volume = "368",
pages = "22--33",
journal = "THE NEW ENGLAND JOURNAL OF MEDICINE",
issn = "0028-4793",
publisher = "Boston: Massachusetts Medical Society",
}
